AQST
(NASDAQ)
4.84
-0.37   (-7.10%)
Pre-market: .00 -4.84 (-100.00%)
Volume (24h) Market Cap. Day Range 52w Range
568.74K 162.72M 4.76 - 5.17 1.41 - 10.00
Oct-28-20 04:33PM Aquestive Therapeutics (AQST) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks
Oct-19-20 11:21AM Aquestive Therapeutics, Inc. (NASDAQ:AQST): Is Breakeven Near?Simply Wall St.
Oct-14-20 11:30AM Aquestive Therapeutics to Announce Third Quarter Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ETGlobeNewswire
Sep-30-20 03:00PM Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Aquestive Therapeutics, Inc. (AQST) InvestigationACCESSWIRE
Sep-29-20 10:06PM Aquestive Therapeutics: Libervant Will Eventually Be Approved, Says AnalystTipRanks
Sep-28-20 08:25AM Aquestive Plunges 37% As FDA Rejects Seizure Drug; Street Stays BullishSmarterAnalyst
Sep-25-20 09:38PM Aquestive Therapeutics Receives Complete Response Letter from FDA for Libervant™ (diazepam) Buccal Film for Management of Seizure ClustersGlobeNewswire
12:51PM Implied Volatility Surging for Aquestive Therapeutics (AQST) Stock OptionsZacks
Sep-17-20 02:11PM 3 “Strong Buy” Healthcare Stocks With Major Catalysts ApproachingTipRanks
Aug-20-20 12:11PM Are Insiders Buying Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stock?Simply Wall St.
11:30AM Aquestive Therapeutics Initiates Phase 1 Pharmacokinetic Trial of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) In Development for Treatment of Allergic Reactions Including AnaphylaxisGlobeNewswire
Aug-18-20 03:06PM Aquestive Therapeutics (AQST) in Focus: Stock Moves 6.4% HigherZacks
Aug-10-20 11:30AM Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Treatment of Allergic Reactions Including AnaphylaxisGlobeNewswire
Aug-05-20 10:31PM Aquestive Therapeutics, Inc. (AQST) Q2 2020 Earnings Call TranscriptMotley Fool
Aug-04-20 11:35PM Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue EstimatesZacks
08:01PM Aquestive Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update: AQST-108 Progress Remains On Track; Libervant PDUFA Goal Date ApproachesGlobeNewswire
Aug-04-20 12:18PM The Daily Biotech Pulse: Voyager, AbbVie End Collaboration, Thumbs Down For DBV's Peanut Allergy Patch, Tiziana Expedites COVID-19 Trial PlansBenzinga
Jul-28-20 08:15PM Aquestive Therapeutics to Present at 2020 Wedbush PacGrow Healthcare Virtual ConferenceGlobeNewswire
04:33PM Aquestive Therapeutics (AQST) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks
Jul-15-20 11:57AM Aquestive Therapeutics to Announce Second Quarter Financial Results and Recent Business Highlights on Aug 4 and Host Conference Call on Aug 5 at 8:00 a.m. ETGlobeNewswire
Jul-06-20 01:49PM What Is The Ownership Structure Like For Aquestive Therapeutics, Inc. (NASDAQ:AQST)?Simply Wall St.
Jun-29-20 11:00AM Aquestive Therapeutics Files IND for Pharmacokinetic Clinical Trials of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis TreatmentGlobeNewswire
Jun-25-20 03:22PM Hedge Funds Aren’t Crazy About Aquestive Therapeutics, Inc. (AQST) AnymoreInsider Monkey
Jun-16-20 12:00PM Aquestive Therapeutics to Present at BMO Capital Markets 2020 Prescriptions for Success Healthcare ConferenceGlobeNewswire
Jun-04-20 09:05PM Aquestive Therapeutics to Hold Virtual-Only Annual Meeting of StockholdersGlobeNewswire
May-28-20 01:42PM Implied Volatility Surging for Aquestive Therapeutics (AQST) Stock OptionsZacks
May-27-20 01:22PM Why Aquestive Therapeutics (AQST) Stock Might be a Great PickZacks
May-22-20 11:10AM The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID FrayBenzinga
May-21-20 09:27PM Aquestive Therapeutics Advances Royalty Monetization Plan as Sunovion Pharmaceuticals’ Apomorphine Sublingual Film Therapy Receives FDA ApprovalGlobeNewswire
May-20-20 03:30PM Is Aquestive Therapeutics (AQST) Outperforming Other Medical Stocks This Year?Zacks
May-14-20 12:25PM Aquestive Therapeutics' Shares March Higher, Can It Continue?Zacks
May-12-20 04:00PM All You Need to Know About Aquestive Therapeutics (AQST) Rating Upgrade to BuyZacks
May-08-20 12:15PM Benzinga Pro's Top 5 Stocks To Watch For Fri., May 8, 2020: KC, IDXX, LAZY, AQST, ANBenzinga
May-07-20 06:00PM Aquestive Therapeutics to Present at 2020 RBC Capital Markets Global Healthcare ConferenceGlobeNewswire
May-06-20 10:00PM Aquestive Therapeutics, Inc. (AQST) Q1 2020 Earnings Call TranscriptMotley Fool
May-05-20 08:05PM Aquestive Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update: AQST-108 and Libervant Remain On TrackGlobeNewswire
Apr-28-20 04:34PM Will Aquestive Therapeutics (AQST) Report Negative Earnings Next Week? What You Should KnowZacks
Apr-26-20 11:51AM 3 Biotech Stocks Under $4 With Big Upside PotentialTipRanks
Apr-21-20 01:15PM Aquestive Therapeutics to Announce First Quarter Financial Results and Recent Business Highlights on May 5 and Host Investment Community Conference Call on May 6GlobeNewswire
Apr-15-20 12:50PM Aquestive Therapeutics (AQST): Strong Industry, Solid Earnings Estimate RevisionsZacks
Apr-14-20 01:13PM Top Ranked Momentum Stocks to Buy for April 14thZacks
Mar-17-20 11:00AM Memgen Appoints Gregory Brown as Chief Executive OfficerNewsfile
Mar-14-20 12:15PM Aquestive Therapeutics, Inc. Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?Simply Wall St.
Mar-13-20 02:23PM Company News for Mar 13, 2020Zacks
Mar-11-20 10:25PM Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue EstimatesZacks
08:30PM Aquestive Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business HighlightsGlobeNewswire
Mar-03-20 08:00PM 7 Cheap Stocks Under $7 With Massive Upside PotentialKiplinger
Feb-20-20 12:00PM Aquestive Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights on March 12, 2020GlobeNewswire
Feb-10-20 12:00PM Aquestive Therapeutics Announces U.S. Food and Drug Administration Filing Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal FilmGlobeNewswire
Feb-06-20 12:00PM Aquestive Therapeutics Announces FDA Confirmed 505(b)(2) Pathway for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis TreatmentGlobeNewswire
Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. Its proprietary product candidates that are in development comprise AQST-203, a buccally, an administered soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; AQST-120, an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy; and AQST-117, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's development products also include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; AQST-305, a buccal film formulation of octreotide for the treatment of acromegaly and neuroendocrine tumors; APL-130277, a sublingual film formulation of apomorphine to treat episodic off-periods in Parkinson's disease; AQST-119, an oral soluble film formulation of tadalafil to treat erectile dysfunction; and AQST-306, a film formulation of edaravone. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.
Cap:    |  Volume (24h):